Adma Biologics Inc (ADMA) concluded trading on Wednesday at a closing price of $17.68, with 4.51 million shares of worth about $79.69 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 2.14% during that period and on March 05, 2025 the price saw a gain of about 3.94%. Currently the company’s common shares owned by public are about 236.62M shares, out of which, 228.00M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Stock saw a price change of 12.04% in past 5 days and over the past one month there was a price change of 7.35%. Year-to-date (YTD), ADMA shares are showing a performance of 3.09% which increased to 220.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.68 but also hit the highest price of $23.64 during that period. The average intraday trading volume for Adma Biologics Inc shares is 2.38 million. The stock is currently trading 9.10% above its 20-day simple moving average (SMA20), while that difference is up 5.58% for SMA50 and it goes to 10.42% higher than SMA200.
Adma Biologics Inc (NASDAQ: ADMA) currently have 236.62M outstanding shares and institutions hold larger chunk of about 86.69% of that.
The stock has a current market capitalization of $4.18B and its 3Y-monthly beta is at 0.63. PE ratio of stock for trailing 12 months is 21.71, while it has posted earnings per share of $0.81 in the same period. Its PEG reads 0.70 and has Quick Ratio of 2.90 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADMA, volatility over the week remained 10.57% while standing at 5.41% over the month.
Stock’s fiscal year EPS is expected to rise by 43.56% while it is estimated to increase by 41.90% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on July 19, 2023 offering a Strong buy rating for the stock and assigned a target price of $5 to it. Coverage by Mizuho stated Adma Biologics Inc (ADMA) stock as a Buy in their note to investors on October 13, 2022, suggesting a price target of $5 for the stock. On November 11, 2021, Raymond James Upgrade their recommendations, while on November 09, 2021, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $4.50. Stock get a Buy rating from Jefferies on June 04, 2019.
